drugset / Trial / NCT07609706
A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of the clinical trial is to collect safety data and information on how the body processes BVd in people with multiple myeloma (MM) who have moderate liver problems, compared with similar participants who have normal liver function. It also compares how liver problems affect the body's handling of belantamab mafodotin and uses the results to help set safe and appropriate dosing guidance for MM participants with moderate liver problems.
Timeline
- Start
- 2026-10-23
- Primary completion
- 2031-08-22
- Completion
- 2031-08-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Belantamab mafodotin | Monoclonal antibody | — | — |
| Background | Bortezomib | Small molecule | — | — |
| Background | Dexamethasone | Small molecule | — | — |